WebSite Ethiopia: 2016

Monday, October 24, 2016

Luveris

Luveris is a brand name of lutropin alfa, approved by the FDA in the following formulation(s):

LUVERIS (lutropin alfa - injectable; subcutaneous)

Manufacturer: EMD SERONO

Approval date: October 8, 2004

Strength(s): 75 IU/VIAL ^[RLD]

Has a generic version of Luveris been approved?

No. There is currently no therapeutically equivalent version of Luveris available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Luveris. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
Patent 5,767,251
Issued: June 16, 1998
Inventor(s): Reddy; Vermuri B. & Hsiung; Nancy & Beck; Anton K. & Bernstine; Edward George
Assignee(s): Genzyme Corporation
Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
Patent expiration dates:
- June 16, 2015
  ✓
  Drug substance

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- October 8, 2011 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Lovaza been approved?

No. There is currently no therapeutically equivalent version of Lovaza available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lovaza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Fatty acid composition
Patent 5,502,077
Issued: March 26, 1996
Inventor(s): Breivik; Harald & Borretzen; Bernt & Dahl; Knut H. & Krokan; Hans E. & Bonaa; Kaare H.
Assignee(s): Norsk Hydro A.S.
Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.
Patent expiration dates:
- March 26, 2013
  ✓
  Patent use: USE IN LIPID MANAGEMENT
  ✓
  Drug substance

Fatty acid composition
Patent 5,656,667
Issued: August 12, 1997
Inventor(s): Breivik; Harald & B.o slashed.rretzen; Bernt & Dahl; Knut Helk.ang.s & Krokan; Hans Einar & B.o slashed.naa; Kaare Harald
Assignee(s): Norsk Hydro as
Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.
Patent expiration dates:
- April 10, 2017
  ✓
  Patent use: USE IN LIPID MANAGEMENT
  ✓
  Drug substance
  ✓
  Drug product

Pharmaceutical composition comprising low concentrations of environmental pollutants
Patent 7,732,488
Issued: June 8, 2010
Inventor(s): Breivik; Harald & Thorstad; Olav
Assignee(s): Pronova Biopharma Norge AS
The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide, a free fatty acid and a hydro-carbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of environmental pollutant present in the fat or oil, being edible or for use in cosmetics, is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile environmental pollutants decreasing working fluid, for use in decreasing an amount of environmental pollutants present in a fat or oil, being edible or for use in cosmetics. In addition, the present invention relates to a health supplement, a pharmaceutical and an animal feed product prepared according to the process mentioned above.
Patent expiration dates:
- January 30, 2025
  ✓
  Drug substance
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- September 16, 2012 - INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION

Has a generic version of LoSeasonique been approved?

A generic version of LoSeasonique has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to LoSeasonique and have been approved by the FDA:

LEVONORGESTREL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet; oral)

Manufacturer: LUPIN LTD

Approval date: October 26, 2011

Strength(s): 0.02MG,0.01MG;0.1MG,N/A ^[AB]

Manufacturer: WATSON LABS

Approval date: October 25, 2011

Strength(s): 0.02MG,0.01MG;0.1MG,N/A ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of LoSeasonique. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Patent 7,615,545
Issued: November 10, 2009
Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
Assignee(s): Duramed Pharmaceuticals, Inc.
This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
Patent expiration dates:
- June 15, 2023
  ✓
  Patent use: PREVENTION OF PREGNANCY

Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
Patent 7,855,190
Issued: December 21, 2010
Inventor(s): Bell; Robert G. & Ben-Maimon; Carole S. & Iskold; Beata & Bronnenkant; Lance J. & Hait; Howard & Reape; Kathleen Z.
Assignee(s): Teva Women's Health, Inc.
The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
Patent expiration dates:
- December 5, 2028
  ✓
  Patent use: PREVENTION OF PREGNANCY

Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Patent 7,858,605
Issued: December 28, 2010
Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
Assignee(s): Teva Women's Health, Inc.
This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
Patent expiration dates:
- June 23, 2023
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- October 24, 2011 - NEW PRODUCT

Has a generic version of Lybrel been approved?

A generic version of Lybrel has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Lybrel and have been approved by the FDA:

LEVONORGESTREL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet; oral)

Manufacturer: WATSON LABS

Approval date: June 6, 2011

Strength(s): 0.02MG;0.09MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lybrel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Hormonal contraceptive
Patent 6,500,814
Issued: December 31, 2002
Inventor(s): Rolf-Dieter; Hesch
Assignee(s): Wyeth Pharmaceuticals
The present invention relates to a hormonal contraceptive product having two hormonal components, an estrogen and a gestagen, and a process for the combined, continuous administration of the product of the invention.
Patent expiration dates:
- September 3, 2018
  ✓
  Patent use: PREVENTION OF PREGNANCY

Has a generic version of Restoril been approved?

Yes. The following products are equivalent to Restoril:

temazepam capsule; oral

Manufacturer: ACTAVIS ELIZABETH

Approval date: August 7, 1987

Strength(s): 15MG ^[AB], 30MG ^[AB]

Manufacturer: MUTUAL PHARM

Approval date: September 8, 2009

Strength(s): 7.5MG ^[AB]

Manufacturer: MUTUAL PHARM

Approval date: September 14, 2009

Strength(s): 22.5MG ^[AB]

Manufacturer: MYLAN

Approval date: July 7, 1986

Strength(s): 15MG ^[AB]

Manufacturer: MYLAN

Approval date: July 10, 1986

Strength(s): 30MG ^[AB]

Manufacturer: MYLAN

Approval date: June 12, 2009

Strength(s): 22.5MG ^[AB]

Manufacturer: MYLAN

Approval date: May 21, 2010

Strength(s): 7.5MG ^[AB]

Manufacturer: NOVEL LABS INC

Approval date: April 21, 1987

Strength(s): 15MG ^[AB], 30MG ^[AB]

Manufacturer: SANDOZ

Approval date: January 12, 1988

Strength(s): 15MG ^[AB], 30MG ^[AB]

Manufacturer: WATSON LABS

Approval date: May 21, 1993

Strength(s): 15MG ^[AB], 30MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Restoril. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Restoril.

Has a generic version of Azor been approved?

No. There is currently no therapeutically equivalent version of Azor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Azor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
Patent 5,616,599
Issued: April 1, 1997
Inventor(s): Yanagisawa; Hiroaki & Fujimoto; Koichi & Amemiya; Yoshiya & Shimoji; Yasuo & Kanazaki; Takuro & Koike; Hiroyuki & Sada; Toshio
Assignee(s): Sankyo Company, Limited
Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.
Patent expiration dates:
- April 25, 2016
  ✓
  Patent use: TREATMENT OF HYPERTENSION
  ✓
  Drug substance
  ✓
  Drug product
- October 25, 2016
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- September 26, 2010 - NEW COMBINATION

Has a generic version of Differin been approved?

A generic version of Differin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Differin and have been approved by the FDA:

adapalene cream; topical

Manufacturer: FOUGERA PHARMS

Approval date: June 30, 2010

Strength(s): 0.1% ^[AB]

adapalene gel; topical

Manufacturer: GLENMARK GENERICS

Approval date: July 1, 2010

Strength(s): 0.1% ^[AB]

Manufacturer: PLIVA HRVATSKA DOO

Approval date: June 2, 2010

Strength(s): 0.1% ^[AB]

Note: No generic formulation of the following product is available.

adapalene - lotion; topical

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Differin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Patent 7,579,377
Issued: August 25, 2009
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefore, advantageously topically applicable gels, creams or lotions.
Patent expiration dates:
- February 23, 2025
  ✓
  Patent use: TOPICAL TREATMENT OF ACNE VULGARIS

Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Patent 7,737,181
Issued: June 15, 2010
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
Patent expiration dates:
- August 29, 2024
  ✓
  Drug product

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders
Patent 7,834,060
Issued: November 16, 2010
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
Patent expiration dates:
- March 12, 2023
  ✓
  Patent use: TREATMENT OF ACNE

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Patent 7,838,558
Issued: November 23, 2010
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development S.N.C.
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
Patent expiration dates:
- March 12, 2023
  ✓
  Drug product

Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
Patent 7,868,044
Issued: January 11, 2011
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
Patent expiration dates:
- March 12, 2023
  ✓
  Patent use: TREATMENT OF ACNE

Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers
Patent 7,998,467
Issued: August 16, 2011
Inventor(s): Mallard; Claire & Ferrara; Eve
Assignee(s): Galderma Research & Development
Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.
Patent expiration dates:
- May 31, 2028
  ✓
  Patent use: TREATMENT OF ACNE
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- March 17, 2013 - NEW DOSAGE FORM

Has a generic version of Dificid been approved?

No. There is currently no therapeutically equivalent version of Dificid available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dificid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Polymorphic crystalline forms of tiacumicin B
Patent 7,378,508
Issued: May 27, 2008
Inventor(s): Chiu; Yu-Hung & Che; Tessie Mary & Romero; Alex & Ichikawa; Yoshi & Shue; Youe-Kong
Assignee(s): Optimer Pharmaceuticals, Inc.
The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.
Patent expiration dates:
- July 31, 2027
  ✓
  Drug substance
  ✓
  Drug product

Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Patent 7,863,249
Issued: January 4, 2011
Inventor(s): Chiu; Yu-Hung & Che; Tessie Mary & Romero; Alex & Ichikawa; Yoshi & Shue; Youe-Kong
Assignee(s): Optimer Pharmaceuticals, Inc.
The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.
Patent expiration dates:
- July 31, 2027
  ✓
  Drug substance
  ✓
  Drug product

18-membered macrocycles and analogs thereof
Patent 7,906,489
Issued: March 15, 2011
Inventor(s): Shue; Youe-Kong & Hwang; Chan-Kou & Chiu; Yu-Hung & Romero; Alex & Babakhani; Farah & Sears; Pamela & Okumu; Franklin
Assignee(s): Optimer Pharmaceuticals, Inc.
The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.
Patent expiration dates:
- March 4, 2027
  ✓
  Patent use: TREATMENT OF MICROBIAL INFECTIONS

Related Exclusivities

Exclusivity expiration dates:
- May 27, 2016 - NEW CHEMICAL ENTITY

Has a generic version of Sumavel DosePro been approved?

No. There is currently no therapeutically equivalent version of Sumavel DosePro available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sumavel DosePro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Needle-less injector
Patent 5,891,086
Issued: April 6, 1999
Inventor(s): Weston; Terence Edward
Assignee(s): Weston Medical Limited
In a needle-less injector combining an actuator and a medicament cartridge, the actuator includes a housing with a forward portion to which the cartridge is connected. An impact member is mounted within the housing inward of the forward portion so as to be movable toward the forward portion, where it may strike components of the cartridge to effect expulsion of a dose of medicament. A chamber is provided within the housing and is pre-filled with a pressurized gas which is in communication with and exerts a constant force on the impact member, tending to urge it towards the forward portion. Movement of the impact member is prevented by a latch which normally engages the impact member and prevents its forward movement, but is actuable to be moved out of such engagement, permitting movement of the impact member, the cartridge includes a piston which is mounted in the body of the cartridge with an interference fit and is made of a material which is substantially non-resilient when subjected to a slowly applied force, but is highly resilient when subjected to a rapidly applied force.
Patent expiration dates:
- July 27, 2014
  ✓
  Drug product

Spring-Powered dispensing device
Patent 5,957,886
Issued: September 28, 1999
Inventor(s): Weston; Terence Edward
Assignee(s): Weston Medical Limited
A needleless injector is described for dispensing a liquid material, comprising a dispensing member which moves under the force of a spring providing an energy store. A damping arrangement, employing a viscous damping medium such as grease, is used to damp recoil during dispensing.
Patent expiration dates:
- March 8, 2016
  ✓
  Drug product

Spring-powered dispensing device for medical purposes
Patent 6,135,979
Issued: October 24, 2000
Inventor(s): Weston; Terence Edward
Assignee(s): Weston Medical Limited
A dispensing device, such as a needleless injector, comprising a spring, which provides an energy store, and a dispensing member movable, to effect a dispensing, under the force of the spring. A latch has a first position in which it restrains movement of the dispensing member and a second position in which it permits such movement. A trigger is operable by the user for moving the latch from the first position to the second position. A safety mechanism, preferably in the form of an appropriately shaped slot in the dispensing member, is effective before the device has been completely assembled to prevent movement of the latch to the second position.
Patent expiration dates:
- March 21, 2017
  ✓
  Drug product

Device for readying a needle free injector for delivery
Patent 7,776,007
Issued: August 17, 2010
Inventor(s): Schuster; Jeffrey A. & Bridges; Paul Stuart & Gibbins; Graham & Reid; Nicola
Assignee(s): Zogenix, Inc.
A needle-free injector device comprising a latch having a safe position which disables the triggering of the device, and a ready position which restrains movement of a dispensing member but enables triggering and a triggered position which permits movement of the dispensing member is disclosed. An additional safety mechanism blocks the triggering of the device until removed. A cap is provided to maintain the sterility and stability of the drug formulation and is configured such that the cap removal is required prior to placing the device in a ready to trigger state.
Patent expiration dates:
- November 28, 2026
  ✓
  Drug product

Casing
Patent 7,901,385
Issued: March 8, 2011
Inventor(s): Anderson; Gregor John McLennan & Mitchell; John
Assignee(s): Zogenix, Inc.
A casing (50) for an injection device (10) of the type having a safety device which prevents operation of the device (10), incorporating an actuator means (56) by which the safety means of the device (10) can be actuated to allow operation of the device (10). Also a casing (50) for a medicament container having an opening closed prior to use by a break-off tip (135), having relatively moveable first and second casing parts (51, 52), which on relative movement apply a breaking force to the break-off tip (135). A preferred embodiment includes both such features.
Patent expiration dates:
- July 31, 2026
  ✓
  Drug product

Has a generic version of Synercid been approved?

No. There is currently no therapeutically equivalent version of Synercid available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Synercid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Synercid.

Has a generic version of Stromectol been approved?

No. There is currently no therapeutically equivalent version of Stromectol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Stromectol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Stromectol.

Has a generic version of Supprelin LA been approved?

No. There is currently no therapeutically equivalent version of Supprelin LA available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Supprelin LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Compositions and methods for treating precocious puberty
Patent 8,062,652
Issued: November 22, 2011
Inventor(s): Kuzma; Petr
Assignee(s): Endo Pharmaceuticals Solutions Inc.
The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
Patent expiration dates:
- June 16, 2026
  ✓
  Patent use: METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

Related Exclusivities

Exclusivity expiration dates:
- May 3, 2014 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Ziagen been approved?

No. There is currently no therapeutically equivalent version of Ziagen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ziagen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Therapeutic nucleosides
Patent 5,034,394
Issued: July 23, 1991
Inventor(s): Daluge; Susan M.
Assignee(s): Burroughs Wellcome Co.
The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
Patent expiration dates:
- December 18, 2011
  ✓
  Drug substance
  ✓
  Drug product
- June 18, 2012
  ✓
  Pediatric exclusivity

Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Patent 6,294,540
Issued: September 25, 2001
Inventor(s): Brodie; Alastair Couper & Jones; Martin Francis & Seager; John Frederick & Wallis; Christopher John
Assignee(s): Glaxo Wellcome Inc.
The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
Patent expiration dates:
- May 14, 2018
  ✓
  Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
  ✓
  Drug substance
  ✓
  Drug product
- November 14, 2018
  ✓
  Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
  ✓
  Pediatric exclusivity

Pharmaceutical compositions
Patent 6,641,843
Issued: November 4, 2003
Inventor(s): Nikki Thoennes; Brooks
Assignee(s): SmithKline Beecham Corporation
The present invention relates to pharmaceutical compostions of (1S,4R)-cis-4-[2-amino-6-cyclopropylamino}-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89).
Patent expiration dates:
- February 4, 2019
  ✓
  Drug product
- August 4, 2019
  ✓
  Pediatric exclusivity

Has a generic version of Isovue-250 been approved?

Yes. The following products are equivalent to Isovue-250:

IOPAMIDOL-250 (iopamidol injectable; injection)

Manufacturer: APP PHARMS

Approval date: April 2, 1997

Strength(s): 51% ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Isovue-250. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Isovue-250.

Has a generic version of Isopto Carpine been approved?

No. There is currently no therapeutically equivalent version of Isopto Carpine available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Isopto Carpine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Isopto Carpine.

Has a generic version of Transderm-Scop been approved?

No. There is currently no therapeutically equivalent version of Transderm-Scop available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Transderm-Scop. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Transderm-Scop.

Has a generic version of Fuzeon been approved?

No. There is currently no therapeutically equivalent version of Fuzeon available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fuzeon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Synthetic peptide inhibitors of HIV transmission
Patent 5,464,933
Issued: November 7, 1995
Inventor(s): Bolognesi; Dani P. & Matthews; Thomas J. & Wild; Carl T.
Assignee(s): Duke University
The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP-178 (SEQ ID:1) ptides corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP-178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
Patent expiration dates:
- June 7, 2013

Synthetic peptide inhibitors of HIV transmission
Patent 6,133,418
Issued: October 17, 2000
Inventor(s): Bolognesi; Dani Paul & Matthews; Thomas James & Wild; Carl T.
Assignee(s): Duke University
The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP-178 (SEQ ID:1) ptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP-178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
Patent expiration dates:
- November 17, 2014
  ✓
  Drug substance
  ✓
  Drug product

Treatment of HIV and other viral infections using combinatorial therapy
Patent 6,475,491
Issued: November 5, 2002
Inventor(s): M. Ross; Johnson & Dennis Michael; Lambert
Assignee(s): Trimeris, Inc.
Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic agent. The combinations of the invention are better than single therapies alone, and in certain cases are synergistic. The use of DP-178 or DP-107 is an ideal therapy to combine with another antiviral, given both the novel mechanism which this therapeutic blocks HIV transmission and the non-toxicity of the therapeutic.
Patent expiration dates:
- June 7, 2015
  ✓
  Patent use: TREATMENT OF HIV

Has a generic version of Terazol 3 been approved?

Yes. The following products are equivalent to Terazol 3:

terconazole cream; vaginal

Manufacturer: TARO

Approval date: April 6, 2004

Strength(s): 0.8% ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Terazol 3. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Terazol 3.

Has a generic version of Triostat been approved?

Yes. The following products are equivalent to Triostat:

liothyronine sodium injectable; injection

Manufacturer: X GEN PHARMS

Approval date: August 17, 2005

Strength(s): EQ 0.01MG BASE/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Triostat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Triostat.

Friday, October 21, 2016

VisionBlue

VisionBlue is a brand name of trypan blue ophthalmic, approved by the FDA in the following formulation(s):

VISIONBLUE (trypan blue - solution; ophthalmic)

Manufacturer: DORC

Approval date: December 16, 2004

Strength(s): 0.06% ^[RLD]

Has a generic version of VisionBlue been approved?

No. There is currently no therapeutically equivalent version of VisionBlue available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of VisionBlue. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with VisionBlue.

Has a generic version of Ventavis been approved?

No. There is currently no therapeutically equivalent version of Ventavis available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ventavis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ventavis.

Related Exclusivities

Exclusivity expiration dates:
- December 29, 2011 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Norpace been approved?

Yes. The following products are equivalent to Norpace:

disopyramide phosphate capsule; oral

Manufacturer: TEVA

Approval date: February 22, 1985

Strength(s): EQ 100MG BASE ^[AB], EQ 150MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: May 31, 1985

Strength(s): EQ 100MG BASE ^[AB], EQ 150MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Norpace. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Norpace.

Has a generic version of Norflex been approved?

Yes. The following products are equivalent to Norflex:

orphenadrine citrate injectable; injection

Manufacturer: AKORN

Approval date: May 24, 2006

Strength(s): 30MG/ML ^[AP]

Manufacturer: BEDFORD LABS

Approval date: March 4, 2003

Strength(s): 30MG/ML ^[AP]

Manufacturer: SAGENT PHARMS

Approval date: August 30, 2011

Strength(s): 30MG/ML ^[AP]

Manufacturer: WATSON LABS

Approved Prior to Jan 1, 1982

Strength(s): 30MG/ML ^[AP]

Manufacturer: WATSON LABS

Approval date: March 15, 1982

Strength(s): 30MG/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Norflex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Norflex.

Has a generic version of Novolog been approved?

No. There is currently no therapeutically equivalent version of Novolog available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Novolog. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Insulin analogues
Patent 5,618,913
Issued: April 8, 1997
Inventor(s): Brange; Jens J. V. & Norris; Kjeld & Hansen; Mogens T.
Assignee(s): Novo Nordisk A/S
Novel rapid-acting human insulin analogues are provided having less tendency to self-association into dimers, tetramers, hexamers, or polymers. The novel human insulin analogues are formed by substituting one or more of the amino acid residues of human insulin with naturally occuring amino acid residues. The amino acid residue substitutions are preferably more hydrophilic than the natural amino acid residue at the respective position in the molecule. Furthermore, the insulin analogues have the same charge or a greater negative charge at neutral pH than that of human insulin. Preferred amino acid substitutions are Asp, Glu, Ser, Thr, His, and Ile, and more preferred substitutions are Asp and Glu. The novel insulin analogues can be used for the preparation of rapid-acting insulin solutions.
Patent expiration dates:
- June 7, 2014
  ✓
  Drug substance
  ✓
  Drug product
- December 7, 2014
  ✓
  Pediatric exclusivity

Insulin preparations containing NaCl
Patent 5,866,538
Issued: February 2, 1999
Inventor(s): Norup; Elsebeth & Langkj.ae butted.r; Liselotte & Havelund; Svend
Assignee(s): Novo Nordisk A/S
Insulin preparations of superior chemical stability, comprising human insulin or an analogue or derivative thereof, glycerol and/or mannitol, and 5 to 100 mM of a halogenide are disclosed.
Patent expiration dates:
- June 20, 2017
- December 20, 2017
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- March 14, 2011 - PROVIDES FOR PEDIATRIC PUMP USE

Has a generic version of Potiga been approved?

No. There is currently no therapeutically equivalent version of Potiga available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Potiga. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Potiga.

Related Exclusivities

Exclusivity expiration dates:
- June 10, 2016 - NEW CHEMICAL ENTITY

Has a generic version of Loestrin 24 Fe been approved?

A generic version of Loestrin 24 Fe has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Loestrin 24 Fe and have been approved by the FDA:

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ethinyl estradiol; norethindrone acetate tablet; oral)

Manufacturer: WATSON LABS

Approval date: September 1, 2009

Strength(s): 0.02MG;1MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Loestrin 24 Fe. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
Patent 5,552,394
Issued: September 3, 1996
Inventor(s): Hodgen; Gary D.
Assignee(s): The Medical College of Hampton Roads
A method of female contraception which is characterized by a reduced incidence of breakthrough bleeding after the first cycle involves monophasicly administering a combination of estrogen and progestin for 23-25 consecutive days of a 28 day cycle in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively and in which the weight ratio of estrogen to progestin is at least 1:45 calculated as ethinyl estradiol to norethindrone acetate.
Patent expiration dates:
- July 22, 2014
  ✓
  Patent use: PREVENTION OF PREGNANCY

Monday, October 24, 2016

LUVERIS (lutropin alfa - injectable; subcutaneous)

Has a generic version of Luveris been approved?

Related Patents

Related Exclusivities

See also...

LOVAZA (omega-3-acid ethyl esters - capsule; oral)

Has a generic version of Lovaza been approved?

Related Patents

Related Exclusivities

See also...

LOSEASONIQUE (ethinyl estradiol; levonorgestrel - tablet; oral)

Has a generic version of LoSeasonique been approved?

LEVONORGESTREL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet; oral)

Related Patents

Related Exclusivities

See also...

LYBREL (ethinyl estradiol; levonorgestrel - tablet; oral)

Has a generic version of Lybrel been approved?

LEVONORGESTREL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet; oral)

Related Patents

See also...

RESTORIL (temazepam - capsule; oral)

Has a generic version of Restoril been approved?

temazepam capsule; oral

Related Patents

See also...

AZOR (amlodipine besylate; olmesartan medoxomil - tablet; oral)

Has a generic version of Azor been approved?

Related Patents

Related Exclusivities

See also...

DIFFERIN (adapalene - cream; topical)

DIFFERIN (adapalene - gel; topical)

DIFFERIN (adapalene - lotion; topical)

Has a generic version of Differin been approved?

adapalene cream; topical

adapalene gel; topical

Related Patents

Related Exclusivities

See also...

DIFICID (fidaxomicin - tablet; oral)

Has a generic version of Dificid been approved?

Related Patents

Related Exclusivities

See also...

SUMAVEL DOSEPRO (sumatriptan succinate - injectable; subcutaneous)

Has a generic version of Sumavel DosePro been approved?

Related Patents

See also...

SYNERCID (dalfopristin; quinupristin - injectable; iv (infusion))

Has a generic version of Synercid been approved?

Related Patents

See also...

STROMECTOL (ivermectin - tablet; oral)

Has a generic version of Stromectol been approved?

Related Patents

See also...

SUPPRELIN LA (histrelin acetate - implant; subcutaneous)

Has a generic version of Supprelin LA been approved?

Related Patents

Related Exclusivities

See also...

ZIAGEN (abacavir sulfate - solution; oral)

ZIAGEN (abacavir sulfate - tablet; oral)

Has a generic version of Ziagen been approved?

Related Patents

See also...

ISOVUE-250 (iopamidol - injectable; injection)

Has a generic version of Isovue-250 been approved?

IOPAMIDOL-250 (iopamidol injectable; injection)

Related Patents

See also...

ISOPTO CARPINE (pilocarpine hydrochloride - solution; ophthalmic)

Has a generic version of Isopto Carpine been approved?

Related Patents

See also...

TRANSDERM SCOP (scopolamine - film, extended release; transdermal)

Has a generic version of Transderm-Scop been approved?

Related Patents